-
Sector Analysis
NewNew Drug Approvals and Their Contract Manufacture – 2024 Edition
This report is the 14th edition of our long-running analysis of the CMO industry, using the FDA's NDA approvals as the primary indicator of performance. New Drug Approvals and Their Contract Manufacture (formerly called "CMO Scorecard") is critical for benchmarking the performance of the contract manufacturing organization (CMO) industry and the relative performance of major CMOs. This year's edition includes a discussion of how inflation and increasing global conflict has impacted pharma manufacturers.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ivosidenib in Chondrosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ivosidenib in Chondrosarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ivosidenib in Chondrosarcoma Drug Details: Ivosidenib (Tibsovo / AG-120) acts as an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ivosidenib in Metastatic Bile Duct Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ivosidenib in Metastatic Bile Duct Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ivosidenib in Metastatic Bile Duct Cancer Drug Details: Ivosidenib...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ivosidenib in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ivosidenib in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ivosidenib in Solid Tumor Drug Details: Ivosidenib (Tibsovo / AG-120) acts...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ivosidenib in Low-Grade Glioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ivosidenib in Low-Grade Glioma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ivosidenib in Low-Grade Glioma Drug Details: Ivosidenib (Tibsovo / AG-120) acts...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dabrafenib Mesylate in Hairy Cell Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dabrafenib Mesylate in Hairy Cell Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dabrafenib Mesylate in Hairy Cell Leukemia Drug Details: Dabrafenib...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dabrafenib Mesylate in Follicular Thyroid Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dabrafenib Mesylate in Follicular Thyroid Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dabrafenib Mesylate in Follicular Thyroid Cancer Drug Details: Dabrafenib...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Trametinib Dimethyl Sulfoxide in Hairy Cell Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Trametinib Dimethyl Sulfoxide in Hairy Cell Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Trametinib Dimethyl Sulfoxide in Hairy Cell Leukemia Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Trametinib Dimethyl Sulfoxide in High-Grade Glioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Trametinib Dimethyl Sulfoxide in High-Grade Glioma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Trametinib Dimethyl Sulfoxide in High-Grade Glioma Drug Details: Trametinib...